Direct Oral Anticoagulants, COX-2–Selective NSAIDs, and Gastrointestinal Bleeding in Atrial Fibrillation - Scorecard - MDSpire

Direct Oral Anticoagulants, COX-2–Selective NSAIDs, and Gastrointestinal Bleeding in Atrial Fibrillation

  • By

  • Fabian Maximilian Meinert

  • Jenny Dimakos

  • Ying Cui

  • Kristian B. Filion

  • Christel Renoux

  • Antonios Douros

  • May 26, 2026

  • 0 min

Share

Clinical Scorecard: The Impact of Direct Oral Anticoagulants and COX-2 Inhibiting NSAIDs on Gastrointestinal Bleeding Risks in Atrial Fibrillation Patients

At a Glance

CategoryDetail
Condition
Key MechanismsInhibition of COX-1 and COX-2 enzymes by NSAIDs, affecting gastrointestinal protection.
Target Population
Care Setting

Key Highlights

    Guideline-Based Recommendations

    Diagnosis

      Management

        Monitoring & Follow-up

          Risks

            Patient & Prescribing Data

            Adults diagnosed with NVAF, aged 18 years and older.

            Concomitant use of DOACs and NSAIDs should be approached with caution due to bleeding risks.

            Clinical Best Practices

              Related Resources & Content

              Original Source(s)

              Direct Oral Anticoagulants, COX-2–Selective NSAIDs, and Gastrointestinal Bleeding in Atrial Fibrillation

              • by Fabian Maximilian Meinert, Jenny Dimakos, Ying Cui, Kristian B. Filion, Christel Renoux, Antonios Douros

              • May 26, 2026

              Related Content

              Clinical outcomes of tricuspid transcatheter edge-to-edge repair in patients with tricuspid regurgitation

              Active endothelial and neural regulation of valve biology, health, and disease

              Remote ischemic preconditioning in elderly patients with acute myocardial infarction and transient ischemic attack: a retrospective cohort study